Stay updated with breaking news from Nuclear Export. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has received an average recommendation of “Moderate Buy” from the five ratings firms that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month target […]
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) Director Garen G. Bohlin acquired 41,140 shares of Karyopharm Therapeutics stock in a transaction dated Tuesday, September 12th. The stock was bought at an average price of $1.22 per share, with a total value of $50,190.80. Following the completion of the purchase, the director now directly owns […]
Presenter SpeechMichael Ulz All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Michael Ulz, one of the biotech analysts here, and...
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the...